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Abstract: Zwitterionization of biomaterials has been heightened to a potent tool to develop 11 
biocompatible materials able to inhibit bacterial and non-specific proteins adhesion. This 12 
constitutes a major progress in the biomedical field. This manuscript overviews the main 13 
functionalization strategies that have been reported up to date to design and develop these 14 
advanced biomaterials. On this regard, the recent research efforts dedicated to provide their 15 
surface of zwitterionic nature are summarized by classifying biomaterials in two main groups. First, 16 
we centre on biomaterials in clinical use, concretely bioceramics and metallic implants. Finally, we 17 
revise emerging nanostructured biomaterials, which are receiving growing attention due to their 18 
multifunctionality and versatility mainly in the local drug delivery and bone tissue regeneration 19 
scenarios.  20 
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 22 
1. Introduction 23 
The increased usage of implantable medical devices is likely to result in a rise in the number of 24 
infections associated to these cases. Bacterial contamination during biomaterial implantation is often 25 
inevitable, provoking a battle between host cells and bacteria that may eventually cause the 26 
infection. This is a devastating complication which presents a heterogeneous clinical profile being 27 
considered as the most difficult infection disease to treat with serious clinical and socio-economic 28 
implications [1,2]. Biomaterials-associated infections generally include bacterial adhesion, 29 
colonization and biofilm formation on the biomaterial surfaces. In general, these infections are 30 
mainly caused by different pathogens as Staphylococcus epidermidis and Staphylococcus aureus [3], 31 
although Escherichia coli and Pseudomonas aeruginosa are also present [4]. These bacterial 32 
colonizations result in an inflammatory reaction and are accompanied by significant morbidity and 33 
mortality rate. For all these reasons, there is an urgent need to develop biomaterials with improved 34 
properties able to provide solution to this serious clinical complication [4]. In this sense, preventive 35 
strategies aimed at inhibiting the first stages of any infective process constitute a powerful and 36 
promising alternative to tackle this issue [5].  37 
Much research effort is being dedicated to develop new approaches to modify biomaterial 38 
surface to inhibit the bacterial adhesion. This could be an attractive alternative to antibiotics, which 39 
are associated with severe side effects, that moreover could create bacterial resistance. In this sense, 40 
it has recently been recognized that both nanotopography and chemical surfaces show an essential 41 
role in bacterial adhesion and biofilm formation [6]. In this sense, nanostructured surfaces currently 42 
represent a good alternative as bacterial-repelling surfaces [7,8].These surfaces comprise a variety of 43 
nanotubes- or nanoparticle-based surfaces, and nanostructured coatings [9], which create a 44 
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superhydrophobic surface (also called leaves lotus effect) repelling the bacteria adhesion and 45 
compromising in most of the cases to the host cell-tissue integration [10]. 46 
Concerning chemical modification to create bacterial-repelling surfaces, zwitterionization has 47 
emerged as a revolutionary approach to provide biomaterials of high resistance to nonspecific 48 
protein adsorption, bacterial adhesion and/or biofilm formation [11]. This strategy also allows the 49 
preservation of the biomaterial biocompatibility in terms of host cell adhesion and colonization, 50 
cytotoxicity and differentiation.  51 
The aim of this review manuscript is to describe the different strategies developed so far for the 52 
zwitterionization of biomaterials. First, we focus on biomaterials in clinical use, concretely 53 
bioceramics and metallic implants. Later on, we revise the recent advances on nanostructured 54 
biomaterials, which have gained much attention by the scientific community owing to their great 55 
potential and versatility in local drug delivery and bone tissue regeneration. To understand the 56 
processes underlying the different behaviors of zwitterionic surfaces by repelling bacteria meanwhile 57 
allowing host cell colonization, an overview of the significance of the ‚race for the surface‛ concept 58 
between bacteria and eukaryotic cells is also given. 59 
2. Tuning the surface properties of biomaterials 60 
The biocompatibility of the biomaterials is tightly related to the performance of cells when they 61 
become in contact and adhere to its surface. In this regard, the surface features of these materials, 62 
such as their topography chemistry or surface energy, become essential pillars in their 63 
biocompatibility [6]. Moreover, depending of the bioceramic functionality, the specific requirements 64 
in terms of cells/proteins adhesion are totally different. Therefore, in bone tissue regeneration 65 
applications tuning the biomaterials surface to trigger bone bonding at the same time that inhibiting 66 
bacterial colonization constitutes an exciting challenge to achieve better clinical outcomes.  67 
Bacteria exist in nature under two states: planktonic (free-floating bacteria) and biofilm (sessile 68 
microorganism communities). From all bacteria, just a small fraction (≈1%) exists in the free floating 69 
form, while around the 99% appear forming biofilms [12]. It is important to denote that the primary 70 
and harder barrier in treating S. aureus infections is often attributed to the formation of bacterial 71 
biofilm. In this sense, the biofilms are mainly built by big sessile bacteria communities embedded in 72 
a self-produced extracellular polymeric matrix or glycocalyx [13]. Within the biofilm, bacteria grow 73 
protected from environmental stress and resist attack by antibiotics, disinfectants, and the immune 74 
system. [14]. Biofilm formation involves a sequence of four steps including: i) adhesion, initial 75 
attachment of the bacteria to the surface of the tissue implant; ii) growth, bacterial aggregation and 76 
accumulation in multiple bacterial layers; iii) biofilm maturation and iv) dispersion, detachment of 77 
bacteria from the biofilm and spreading to other places (asepsis state) [15].   78 
In 1987, the orthopedic surgeon Anthony G. Gristina described the concept of "race for the 79 
surface" to predict the evolution of an implant in the specific relation to an infection process [16]. 80 
This concept contemplates "a race" between the eukaryotic cells (host cells) and the bacteria towards 81 
the implant surface, arguing that when the host cells colonize its surface, the probability of bacterial 82 
colonization is very low. However, when the implant is first colonized by the bacteria, it is 83 
irreversibly infected, not allowing the eukaryotic cell to colonize it. Thus, such a concept has 84 
stimulated technological and biomaterial progress while emphasizing the role of implant 85 
biocompatibility and tissue-integration. Thus, the great challenge is to design implants that make the 86 
race being won by eukaryotic cells, covering all biomaterial surfaces at the same time that inhibit 87 
bacterial colonization. However, the ‚race for the surface‛ concept has been criticized for its 88 
simplicity (simple rules) and the static conditions in which it is assessed, being useful notably for 89 
specific purposes as determining surface affinity to different species and the effects of coexistence 90 
[17]. Concerning this issue, the he most destabilizing factor is the great survival rate of the bacteria 91 
since they are able to adhere and survive on any surface [18,19]. 92 
The bacterial adhesion process can be divided into two main phases as reversible and 93 
irreversible stages, being the first phase mechanically and biologically less stable than the second 94 
one [20,21]. The first phase, encompassing the bacteria adhesion and micro-colonies formation, is 95 
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mainly governed by the electrostatic attraction forces between bacteria and surfaces (mediated by 96 
certain proteins like adhesins) and where the electrochemical nature of the biomaterial plays a major 97 
role [22,23]. On the contrary, the second phase is governed by molecular and cellular interactions 98 
closely related with expression of specific gene clusters of the biofilm. They initiate the secretion of 99 
an protective slime formed by mucopolysaccharide layer, which becomes extremely resistant to both 100 
host immune system and antibiotic diffusion [24]. It is important to remark that bacteria cannot 101 
initiate the biofilm-related phenotype before they firmly attach to the implant. Thus, the transition 102 
phase between reversible and irreversible processes of biofilm formation constitutes the last 103 
‚window of opportunity‛ for clinically reasonable preventive treatments. 104 
On the other hand, concerning the host site, the way eukaryotic cells interact with an implant 105 
surface is through an interface that consists of discrete attachment protein points (integrins). These 106 
integrins interact with specific moieties of the extracellular matrix, such as RGD motifs [25], which 107 
contribute to bone regeneration and remodeling processes, being protected against bacterial 108 
colonization. However, neither osseointegration nor fibrous tissue encapsulation of an implant can 109 
eliminate long-term survival of bacterial micro-colonies, which also contribute to a possible delayed 110 
infection. As a result, there is a strong need to design an intrinsic implant with antibacterial 111 
functionality that can overcome and kill these remnant bacteria [26].  112 
Figure 1 shows the process of biomaterial surface colonization by bacteria starting from a 113 
reversible phase where individual floating microorganisms settle down by low stable 114 
adhesin-mediated non-specific interactions with the biomaterial. These first steps delimit a ‚window 115 
of opportunity‛ for almost all antibiofilm strategies, in which is possible to inhibit the final biofilm 116 
formation and to reverse the final destiny of biomaterial for cell colonization. In this sense, if the host 117 
cell win the ‚race for the surface‛, which attain irreversible attachments on the biomaterial surface 118 
first, the presence of a continual cell layer makes it complicated for bacteria adhesion and biofilm 119 
formation.120 
 121 
Figure 1. Concept of ‚race for the surface‛ and significance of ‚window of opportunity‛ in the 122 
development of implants capable to be colonized by host cells, while impede the bacteria adhesion 123 
and formation of the biofilm. 124 
3. Significance of zwitterionization of biomaterials 125 
The development of zwitterionic bioceramics to inhibit unspecific protein adsorption was 126 
reported for the first time in 2010 by Colilla et al. [27]. Previously, Jiang and co-workers had 127 
described the zwitterionization to develop polymeric and metallic biomaterials fulfilling the 128 
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ultralow-fouling criterion (<5 ng/cm2) [28,29]. Zwitterionic surfaces possess an equal number of both 129 
negatively and positively charged groups maintaining overall electrical neutrality, which depends 130 
on the pH of the environment [30].  Their non-fouling properties , as in the case of hydrophilic 131 
materials, are associated to the formation of a hydration layer on surface of biomaterial, forming a 132 
physical and energetic barrier that hinders unspecific proteins adhesion. Recently, zwitterionization 133 
of bioceramics has emerged as a cutting-edge technology to confer surfaces not only of high 134 
resistance to non-specific protein adsorption, but also to bacterial adhesion and/or biofilm formation 135 
(Figure 2) [11,31]. However the main requisite of any biomaterial, biocompatibility, must be kept in 136 
mind, i.e. zwitterionization must prevent bacterial adhesion but allow adequate host cell 137 
colonization. In vitro studies using osteoblastic-like cells revealed that they are able to appropriately 138 
adhere, colonize, and spread onto the surface of these zwitterionic bioceramics [31]. This different 139 
behaviour between prokaryotic and eukaryotic cells are caused by two main reasons [32]: i) the wall 140 
of the bacteria is formed by phospholipids layer, as eukaryotic cells, being much more rigid due to 141 
an external layer of peptidoglycan, ii) bacteria are much smaller in size (ca. 1 µm) than eukaryotic 142 
cells (ca. 50 µm). It has been proven that these both bacteria characteristics could be responsible of 143 
their capacity to discriminate differences in the biomaterials surfaces at the nanoscale level. As it has 144 
been above discussed in section 2, since eukaryotic cells adhere to surfaces via integrins-mediated 145 
mechanisms, bacteria adhesion is mainly driven by electrostatic attractive forces mediated by 146 
adhesions. In this last case, the electrochemistry of the biomaterial surface is an essential factor 147 
governing their adhesion [22,23], which explains the different behaviour compared to eukaryotic 148 
cells. 149 
 150 
Figure 2. Schematic illustration of the different behavior of conventional biomaterial surfaces vs 151 
biomaterials zwitterionic surfaces against bacterial colonization. As bacteria get close to the surface of 152 
conventional biomaterials, they are able to adhere, colonize and forming a biofilm, which is one of 153 
the major concerns in biomaterials associated infections. Oppositely, zwitterionic surfaces provide 154 
biomaterials of bacterial-repelling properties, thus inhibiting the subsequent biofilm formation, 155 
which constitutes a promising alternative in the biomaterials scenario to prevent bacterial infection. 156 
3.1. Chemical strategies for the zwitterionization of biomaterials 157 
In general terms, the zwitterionization of biomaterials involve in the functionalization of their 158 
surfaces at atomic level [11] In the beginning, the research efforts were focused on functionalizing 159 
with zwitterionic polymers bearing mixed positively and negatively charged moieties within the 160 
same chain and overall charge neutrality (Figure 3) [28,29,33-35]. There are three main 161 
methodologies to graft these polymers to the surface of biomaterials: (i) for functionalizing with 162 
poly(sulfobetaine) and polycarboxybetaine derivatives by surface-initiated atom transfer radical 163 
polymerization (SI-ATRP) [36-39]; (ii) for grafting sulfobetaine copolymers by surface reversible 164 
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addition-fragmentation chain transfer (RAFT) through the polymerization method denoted as 165 
graft-from-surface‛ and (iii) more simple procedures through polymerization method 166 
‚graft-to-surface‛*40+.  In this method, polymers carrying adhesive moieties with strong surface 167 
affinity are synthesized and then grafted onto the surface through their adhesive moieties [41,42]. 168 
Furthermore, it is possible to confer biomaterials of zwitterionic nature by decorating their surface 169 
with low-molecular weight moieties bearing the same number of negative and positive charges 170 
(Figure 3). For instance, it is possible to functionalize with different amino acids such as cysteine and 171 
lysine [43-45], sulfobetaine derivatives [45-47] or dopamine [48,50], exhibiting zwitterionic 172 
characteristics depending on the pH. Although the reported methods usually requires several 173 
synthetic steps involving different intermediate products, they offer distinct advantages compared 174 
to zwitterionic polymers, since they are usually associated to relatively more simple methods and 175 
lead to more biocompatible surfaces. A significant advance in the design and development of 176 
zwitterionic surfaces has consisted on the use of more direct and simple grafting methods by 177 
functionalization with organosilanes. In this case, the presence of hydroxyl (-OH) on the biomaterial 178 
surface helps to the simultaneously attach two organosilanes bearing positive and negative charges, 179 
respectively. This strategy allows for tailoring the zwitterionic properties by adjusting the molar 180 
ratio of the two organosilanes used during the synthesis. This process can be accomplished using 181 
two different alternatives, the co-condensation and the post-synthesis route. In the case of 182 
co-condensation method, functionalization takes place at the same time that the biomaterial is being 183 
synthetized. For instance, zwitterionic mesoporous SBA-15 material containing –NH3+/–COO- 184 
groups was synthesized by adding two alkoxysilanes, aminopropyltrimethoxysilane (APTES) and 185 
carboxyethyl silanetriol sodium salt (CES) (Figure 3), together with the tetraethylorthosilicate 186 
(TEOS), as silica precursor, during the synthesis step [27]. Moreover, our research group has also 187 
reported the synthesis of zwitterionic SBA-15 by functionalization with 188 
(N-(2-aminoethyl)-3-aminopropyl-trimethoxysilane) (DAMO) alkoxysilane, which contains primary 189 
and secondary amine groups [52]. As it can be observed in Figure 3 its zwitterionic nature is 190 
provided by the presence of –NH3+/–SiO- and >NH2+/–SiO- zwitterionic pairs. On the other hand, the 191 
post-synthesis route relies on grafting the organosilanes to the biomaterials surface once they have 192 
been synthesized. Following this methodology, zwitterionic hydroxyapatite has been also been 193 
prepared by linking APTES and CES to the P–OH groups present in the surface of this biomaterial 194 
[53]. 195 
 196 
Figure 3. Representative examples of the different chemical strategies developed so far for the 197 
zwitterionization of biomaterials: Grafting of zwitterionic polymers [e.g. 3-(diethylamino)propylamine 198 
(DEAPA) coupled to poly(acrylic acid) (PAA)]; Sulfobetaine siloxane derivatives; Amino acid 199 
derivatives (e.g. cysteine); Mixture of alkoxysilanes [e.g. 3-aminopropyltrimethoxysilane (APTES) 200 
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and carboxyethylsilanetriol sodium salt (CES)]; Alkoxysilane 201 
[N-(2-aminoethyl)-3-aminopropyl-trimethoxysilane) (DAMO)]. 202 
3.2. Zwitterionization of biomaterials to prevent bacterial infection 203 
Currently, one of the major clinical challenges regarding the use of biomaterials is their 204 
custom-made design depending on the biomedical application [54,55]. Bioceramic implants for bone 205 
tissue regeneration, such as those based on calcium phosphates or bioactive glasses, can be 206 
manufactured as three dimensional (3D) scaffolds using rapid prototyping (RP) methods [54]. These 207 
scaffolds exhibit a high percentage of porosity and interconnectivity, and ease to be modulated with 208 
improved mechanical properties compared to scaffolds fabricated by conventional methods [56]. 209 
Moreover, it is possible to combine nanostructural characteristics with micro-macro architecture for 210 
a fine-tuning of cellular behavior [57-58]. However, when facing the regeneration of large and 211 
critical bone defects, bioceramic implants are not suitable due to their intrinsic brittles [54]. It is 212 
feasible to manufacture metallic alloys using these RP methods, providing strong scaffolding to the 213 
bone regenerations purposes with porosities higher than 50% in volume, the rest being engaged by a 214 
metal skeleton [59,60]. In this regard, the milestone in bone tissue regeneration is to design these 3D 215 
scaffolds with surfaces capable of inhibiting and/or abolishing bacterial infection meanwhile 216 
allowing osteoblast cells colonization. This surface would constitutes a great technological advance 217 
to achieve better clinical outcomes. Currently, the scientific community is focussed for the design of 218 
3D scaffolds that dynamically contribute to the regeneration process, stimulating the 219 
osteoconduction and angiogenesis at the same time than evade the bacterial infection [60-63]. 220 
However, the challenge is to provide 3D scaffolds of zwitterionic character. In this sense, 3D 221 
scaffolds based on pure nanocrystalline HA have been successfully constructed with a zwitterionic 222 
nature by post-synthesis grafting of APTES and CES [53], which incorporates both –NH3+ and –COO- 223 
groups on the surface, respectively (Figure 4, Left). To attain this goal, HA 3D scaffolds were first 224 
prepared by using RP technique and then the resulting 3D-HA scaffolds were bifunctionalized by 225 
grafting both alkoxysilanes. Microbiological assays regarding bacterial adhesion using Escherichia 226 
coli (E. coli) showed a noticeable inhibition of 99% with respect to unmodified 3D-HA. The 227 
coexistence of –NH3+/–COO- pairs onto 3D-HA scaffold avails its bacterial-repelling properties. At 228 
the same time, in vitro assays using HOS osteoblastic-like cells cultures demonstrated excellent 229 
biocompatibility as the cells were able to spread and colonize the entire scaffold surface. Scanning 230 
Electron Microscopy (SEM) micrographs show viable osteoblastic-like cells, exhibiting polygonal 231 
shapes with filopodia-like projections attached to the surfaces (Figure 4, Left). Moreover, the cell 232 
migration within the overall 3D-HA structure was demonstrated, showing total colonization of 3D 233 
scaffold at different levels. This zwitterionization approach has been also applied onto Ti6Al4V 234 
3D-scaffolds fabricated also by RP techniques [64]. In this case, to improve the functionalization 235 
capability of the metallic surface, it was previously coated by a HA layer using the dip-coating 236 
method. Once the HA coating was formed onto the Ti6Al4V 3D-scaffold, its surface was 237 
zwitterionized by direct grafting of APTES and CES, following the same procedure as that reported 238 
for pure 3D-HA scaffolds [53]. Again, the presence of zwitterionic pairs inhibits S. aureus adhesion 239 
and biofilm formation, while permiting the osseointegration of this metallic implant, showing 240 
MC3T3-E1 preosteoblasts colonizing the entire scaffold surface. The obtained results indicate that 241 
the zwitterionization process does not affect the biocompatible properties of the metallic Ti6Al4V 242 
3D-scaffolds, showing neither noticeable differences regarding cytotoxicity nor less proliferation 243 
compared to bare 3D scaffold (Figure 4, right). Regarding the biofilm formation capability of these 244 
surfaces, we carried out confocal microscopy to study the biofilm formation after 24 h of incubation 245 
with S. aureus by using directly simultaneously acridine orange (green) and calcofluor (blue) 246 
fluorescent dyes, which label live bacteria and extracellular matrix of biofilms, respectively (Figure 247 
4, Top). The obtained results clearly display the biofilm formation by the blue staining of a typical 248 
extracellular matrix covering the bacterial colonies with a thickness of 15 ± 3.3 m on the Ti6Al4V 249 
scaffolds, while blue staining is absent in Ti-Zwitter scaffolds, revealing the non-formation of the 250 
biofilm after 24 h of assay.  251 
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 252 
Figure 4. Zwitterionization of different biomaterials in clinical use by grafting of 253 
carboxyethylsilanotriol sodium salt (CES) and aminopropyltriethoxysilane (APTES) onto the surface 254 
of these biomaterials. Left: Pure HA 3D Rapid Prototyping (RP) scaffolds. Right: Electron Beam 255 
Melting (EBM) Ti6Al4V 3D scaffolds. 256 
Concerning the regeneration process, we carried out a simple assay by confocal microscopy 257 
using preosteoblast MC3T3-E1 seeded on the surface of these scaffolds and incubated during 7 days. 258 
Both colonization and cell-morphology were studied by staining the cytoskeleton with Atto 259 
565-conjugated phalloidin (red) and nuclei with DAPI (blue) as it can be observed in Figure 5 260 
(bottom). In both casses, the cells display a high spreading grade with a well-built actin cytoskeleton 261 
and high level of colonization in all entire surface of both scaffolds. These results revealed that the 262 
zwitterionization process does not affect the healing process, showing the same behavior that 263 
unmodified Ti [64]. In the case of zwitterionic biomaterials currently under research, nanostructured 264 
bioceramics are receiving growing attention by the scientific community. Among these 265 
nanostructured biomaterials, silica-based mesoporous bioceramics are in the crest of the wave 266 
because of their exceptional features, such as high surface areas and pore volumes, tunable and 267 
narrow pore size distributions and easy-to-functionalize surfaces [65-67]. Therefore they become 268 
excellent candidates to be provided of zwitterionic nature but also to host a great variety of 269 
antibiotics, allowing the combination of bacterial repellent and killing capabilities [68-71].  270 
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 271 
Figure 5. Confocal microscopy images showing of EBM-Ti6Al4V 3D scaffolds before (Ti) and after 272 
being zwitterionized (Ti-Zwitter). In vitro behavior of the biomaterials after being incubated during 24 273 
hours in S. aureus bacteria (Top) and during 4 days in MC3T3-E1 preosteoblast cells (Bottom). The 274 
results reveal the biofilm formation on the Ti surface, appearing the blue coating corresponding to 275 
the polysaccharide matrix (calcofluor), whereas this coating is not observed on the surface of 276 
Ti-zwitter surface, which confirms the antibiofilm formation preventing capability of this material. 277 
Both Ti and Ti-zwitter surfaces undergo an appropriate preosteoblastic colonization and spreading 278 
in the entire surface, with the nuclei stained in blue (DAPI) and the cytoskeleton stained in red 279 
(phalloidin). 280 
Figure 6 shows the performance of zwitterionic SBA-15 (SBA15-Zwitter) nanostructured 281 
bioceramic owning –NH3+/–SiO- and >NH2+/–SiO- pairs [52], provided by the co-condensation 282 
functionalization with the diamine alkoxysilane (DAMO) (Figure 3). This bioceramic exhibits 283 
zwitterionic character at the physiological pH of 7.4, which constitutes a significant advance in this 284 
kind of materials for biomedical applications. In vitro bacterial adhesion tests using S. aureus strains 285 
reveal a great reduction of 99.9% with respect to unmodified SBA-15 (Figure 6). The intrinsic features 286 
of this nanostructured bioceramic permits loading of the broad-spectrum antibiotic, cephalexin, 287 
showing a loading capability of around 13 mg∙g-1 together with a sustained drug release during 288 
more than 15 days. The synergistic combination of zwitterionic nature and antibiotic hosting 289 
capability opens up a new insight in the management of bone-associated infections. 290 
Zwitterionization has been also implemented on mesoporous bioactive glasses (MBG) having the 291 
SiO2-CaO-P2O5 composition [44]. These MBG are a type are nanostructured bioceramics analogous in 292 
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composition to conventional bioglasses but exhibiting outstanding bioactive and cell response 293 
behaviors [69,72]. Thus, Sánchez-Salcedo et al. have recently reported the zwitterionization of MBG 294 
by tethering lysine (MBG-Lys). In vitro bacterial adhesion assays with S. aureus proved a reduction 295 
up to 99.9% compared to unmodified MBG. Moreover, MBG-Lys are cytocompatible, as 296 
demonstrated by in vitro studies carried out with MC3T3-E1 preosteoblasts cultures, which increases 297 
the potential application of these nanostructured bioceramics in bone tissue regeneration. 298 
 299 
Figure 6. Schematic depiction of pure silica SBA-15 and zwitterionic SBA-15 (SBA-Zwitter) 300 
nanostructured materials. SBA-Zwitter was prepared following the co-condensation route in the 301 
presence of DAMO. Counting of colony forming units of S. aureus after 90 min of culture onto SBA-15 302 
and SBA15-Zwitter surfaces. Statistical significance: *p <0.01. Confocal microscopy images of S. 303 
aureus adhered onto SBA-15 and SBA15-Zwitter surfaces after staining with Baclight® KitTM. 304 
4. Conclusions 305 
Zwitterionization is emerging as a powerful strategy to design advanced biomaterials for the 306 
management of infection that is envisioned to result in better clinical outcomes. The possibility to 307 
easily functionalize biomaterials surface at the atomic and nanoscale levels to prevent the 308 
non-specific protein and bacterial adhesion opens up many paths to tackle severe clinical concerns. 309 
Indeed, zwitterionic biomaterials have shown an opposite behaviour by inhibiting bacterial adhesion 310 
while allowing host cells adhesion and colonization of the surface. This fact constitutes the 311 
cornerstone in their potential clinical application, and much research effort is committed to translate 312 
these significant advances from bench to bedside. However, there are certain challenges that these 313 
biomaterials have to face for their clinical stage of development. These challenges include: (i) 314 
preservation of biocompatibility, (ii) adequate pharmacokinetics through the local administration of 315 
antimicrobial agents and (iii) bone healing capacity, which guarantee success in bone regeneration. 316 
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